The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
The9 (Nasdaq: NCTY) reported that shareholders of RF Acquisition Corp II (RFAI) approved the proposed business combination with Nanyang Biologics (NYB) at an extraordinary general meeting on August 19, 2026, advancing NYB’s plan to list on Nasdaq under the ticker “NYB.”
The9 holds its stake in NYB through wholly owned subsidiary Gamenow.net (Hong Kong) Limited and, upon completion of the transaction and satisfaction of customary closing conditions, expects to own approximately 15%–16% of the combined Nasdaq-listed company. NYB applies artificial intelligence to discover novel drug candidates from natural compounds using its Vecura™ AI platform, built on a proprietary library of over one million natural compounds. According to The9, this progress supports its strategy to expand from its core AI-powered gaming ecosystem, the9bit, into broader AI-driven industries such as drug discovery.
Positive
- RFAI shareholders approved NYB business combination at August 19, 2026 EGM
- Expected 15%–16% stake in combined Nasdaq-listed NYB upon deal completion
- Strategic AI diversification extends The9 beyond core gaming into AI-driven drug discovery
- NYB Vecura AI platform leverages library of 1+ million natural compounds
Negative
- Business combination not yet completed and remains subject to customary closing conditions
Details
News Market Reaction – NCTY
On Aug 21, the day this news came out, NCTY closed 32.57% above the previous close. Argus tracked a peak move of +17.4% during that session. Argus tracked a trough of -19.9% from its starting point during tracking. Our momentum scanner recorded 27 alerts for this stock that day. Relative volume reached 3.8x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 21 session.
Key Figures
- Shareholder approval date
- August 19, 2026
- RFAI extraordinary general meeting
- Expected ownership stake
- Approximately 15% to 16%
- The9's expected stake in the combined Nasdaq-listed company
- Natural compound library
- More than one million natural compounds
- Vecura AI platform
Historical Context
-
Scheduled release of second-quarter 2026 results for August 24, 2026
-
SEC effectiveness notice advanced NYB's planned Nasdaq listing process
-
Southeast Asia partnership network reached 41 signed brands
-
Reported US$23 million quarterly net income and sequential growth expectations
-
George Lai became CEO effective July 27, 2026
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
business combination financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Milestone Marks Further Progress in The9's Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today announced that Nanyang Biologics Pte. Ltd. ("NYB"), a Singapore-based, AI-driven drug discovery company in which The9 holds a strategic equity stake, has taken a significant step toward its planned Nasdaq listing. At an extraordinary general meeting held on August 19, 2026, shareholders of RF Acquisition Corp II ("RFAI") voted to approve NYB's proposed business combination, marking a key milestone in NYB's effort to become a Nasdaq-listed company under the reserved ticker symbol "NYB."
The9, which holds a stake in NYB through its wholly owned subsidiary Gamenow.net (Hong Kong) Limited ("Gamenow"), previously announced the investment as part of the Company's strategy of selectively extending into promising AI-driven opportunities beyond its core gaming ecosystem, the9bit. Upon completion of the business combination, which remains subject to customary closing conditions, The9 is expected to hold approximately
NYB specializes in applying artificial intelligence to the discovery of novel drug candidates from natural compounds. Its Vecura™ AI platform, built on a proprietary library of more than one million natural compounds, is designed to identify promising bioactive candidates and mechanisms that conventional, synthetic-first approaches often overlook.
"This vote is an encouraging step forward for NYB and reflects strong shareholder confidence in its business," said George Lai, Chief Executive Officer of The9. "As a long-term investor in NYB, we are pleased to see this investment move closer to the public markets. We see this progress as more than a milestone for NYB alone; it reinforces the value of our investment and widens the range of possibilities for us going forward as we continue to build out The9's presence across the AI sector."
About The9 Limited
The9 Limited (Nasdaq: NCTY) is a global, diversified high-tech company redefining how games are created, played, and monetized. Founded in 1999 and Nasdaq-listed since 2004, The9 brings over two decades of gaming heritage to its flagship platform the9bit, an AI-powered digital asset ecosystem built around AI game creation and the
No Offer or Solicitation
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.
Forward-Looking Statements
This release contains statements that are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management's beliefs and expectations as well as on assumptions made by and data currently available to management, and they appear in a number of places throughout this document and include statements regarding, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. The use of the words "will," "expects," "intends," "anticipates," "estimates," "predicts," "believes," "should," "potential," "may," "forecast," "objective," "plan," or "target," and other similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties that could cause actual results to differ materially. Such statements include, but are not limited to, statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies, future market conditions or economic performance and developments in the capital and credit markets, expected future financial performance, and the markets in which we operate. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including, but not limited to, the following: results of operations, financial condition, our stock price, our strategies, our future business development, competition in the industry in which we operate, our ability to manage our costs and expenses, volatility in the market price of digital assets, the limited liquidity of certain digital asset tokens, evolving and uncertain regulatory frameworks governing cryptocurrencies, digital assets, and token-based economies, laws and regulations relating to the industry in which we operate, general economic and business conditions, and assumptions underlying or related to any of the foregoing. For a discussion of these and other risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statement, see The9's filings with the U.S. Securities and Exchange Commission. The9 undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.
View original content:https://www.prnewswire.com/news-releases/the9s-investee-nanyang-biologics-nyb-advancing-toward-nasdaq-listing-after-rfai-cleared-vote-at-shareholders-extraordinary-general-meeting-302857232.html
SOURCE The9 Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.